Publication highlight: Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
The recently completed phase 3 POSEIDON clinical trial, published in the New England Journal of Medicine Evidence, demonstrated that peanut oral immunotherapy is safe and effective in 1-4 year old children. The POSEIDON trial was conducted at 14 sites in North America (including the Stanford Sean N. Parker Center) and 9 sites in Europe. Furthermore, when the study results were subdivided by age groups, younger children had 1-2 year old had slightly higher rates of tolerating up to 2000 mg of peanut than other age groups (although rates were high overall). Adverse events were frequent but mostly mild, with no serious or severe treatment associated adverse events. Together, these findings demonstrate that peanut oral immunotherapy can be safely and effectively performed in children as young as 1 year old. For more information, please see the full article here: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300145.
By Andrew Chin
Andrew Chin is a scientific grant writer at the Sean N. Parker Center who works closely with Drs. Chinthrajah and Sindher to assist with the Center's manuscripts, grants presentations, and other aspects of scientific writing. His background in basic research allows him to bring complementary insights to the clinical research in the Center.
